Minocycline 1.5% foam for the topical treatment of moderate to severe papulopustular rosacea: Results of 2 phase 3, randomized, clinical trials - 14/04/20
Abstract |
Background |
Efficacious topical medications for rosacea are needed. FMX103 1.5% is a novel topical minocycline foam that may have therapeutic benefits in treating rosacea while minimizing systemic adverse effects due to its topical route of delivery.
Objective |
To determine the efficacy, safety, and tolerability of 12 weeks of treatment with FMX103 1.5% topical minocycline foam for papulopustular rosacea.
Methods |
Two 12-week, phase 3, randomized, multicenter, double-blind, vehicle-controlled, 2-arm studies were performed in patients with moderate to severe papulopustular rosacea.
Results |
Participants who received FMX103 1.5%, versus control individuals treated with vehicle, exhibited a significantly greater reduction in the number of inflammatory lesions (FX2016-11: -17.57 vs -15.65; P = .0031; FX2016-12: -18.54 vs -14.88; P < .0001) and higher rates of Investigator Global Assessment treatment success (FX2016-11: 52.1% vs 43.0%; P = .0273; FX2016-12: 49.1% vs 39.0%; P = .0077). No serious treatment-related treatment-emergent adverse events occurred.
Limitations |
The generalizability of these data from a controlled clinical trial should be examined in a real-world setting.
Conclusions |
FMX103 1.5% was efficacious for moderate to severe papulopustular rosacea and maintained a favorable safety profile.
Le texte complet de cet article est disponible en PDF.Key words : double-blind clinical trial, facial, minocycline, papulopustular rosacea, phase 3, topical foam
Abbreviations used : AE, Cmax, DRESS, IGA, study 11, study 12, TEAE
Plan
| Funding sources: Supported by Foamix Pharmaceuticals, Inc. |
|
| Disclosure: Dr Stein Gold is an advisor, investigator, and consultant for Foamix and Galderma, an investigator for Novartis and Sol Gel, and an advisor and investigator for Ortho-Dermatologics. Dr Del Rosso is a consultant, advisor, and investigator for BioPharmX, Foamix, and Galderma, and a speaker for Galderma. Dr Bhatia served as an investigator for Foamix. Dr Hooper served as an investigator for Foamix, reported personal fees from DelRicht Research during the study, received honoraria from Allergan, Almirall Aesthetics, Aqua Pharmaceuticals, Galderma USA, Cutera, Inc, Ferndale, La Roche Posay, Pixacore, RBC Consultants (clarisonic), Revance, and Viviscal, and received other financial benefits from Actavis, Dermira, GlaxoSmithKline, Mylan, and Sol Gel. Dr Kircik is an investigator and consultant for Foamix. Dr Nahm is an investigator for Foamix. Dr Iain Stuart is an employee and stockholder at Foamix. |
|
| IRB approval status: The study protocol (ClinicalTrials.gov identifier: NCT03142451) was approved by an institutional review board at each site. |
Vol 82 - N° 5
P. 1166-1173 - mai 2020 Retour au numéro
Article précédent
- Meta-analysis of number needed to treat for diagnosis of melanoma by clinical setting
- Amy J. Petty, Bradley Ackerson, Reed Garza, Michael Peterson, Beiyu Liu, Cynthia Green, Michelle Pavlis
- Measurement properties of the Patient-Reported Outcomes Measurement Information System Itch Questionnaire item banks in adults with atopic dermatitis
- Jonathan I. Silverberg, Jin-Shei Lai, Paras P. Vakharia, Kevin Patel, Vivek Singam, Rishi Chopra, Ryan Sacotte, Neha Patel, Supriya Rastogi, Robert Kantor, Derek Y. Hsu, David Cella
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?